Tryp Therapeutics Completes Acquisition by Exopharm Limited

Tryp Therapeutics, Inc. and Exopharm Limited have announced the successful completion of their arrangement wherein Exopharm has acquired Tryp in an all-stock transaction. This arrangement, approved by the Supreme Court of British Columbia and Tryp’s shareholders, became effective on May 1, 2024. According to the terms, Tryp shareholders will receive 3.616 Exopharm ordinary shares for each Tryp share they owned.

Following this arrangement, Tryp shares will be delisted from the Canadian Securities Exchange and cease trading on OTCQB Venture Market. Exopharm shares are set to begin trading on the Australian Securities Exchange under the new name "Tryptamine Therapeutics Limited" and ticker symbol "TYP" starting approximately May 15, 2024. Shareholders are advised to consult their broker or intermediary for details on claiming their new shares.